Autopsy report · NCT04027946
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Cause of deathSlow enrollment
“Study was terminated due to slow accrual.”
Life of this trial
- Registered 2 months before it started.
- Ran for about 4 years 3 months before it stopped.
- 6 participants enrolled.
- Results were posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Lung Cancer; Non-Small Cell Lung Cancer; Adenocarcinoma of Lung
- Interventions
- LMB-100; pembrolizumab; Mesothelin Expression; TrueSight Oncology 500
- Participants
- 6
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
“Study terminated due to slow accrual.” - Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions
“Study was terminated due to slow accrual rate.” - CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
“Study terminated due to slow/insufficient accrual.” - Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension
“Study has been terminated due to poor accrual.” - Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
“Study terminated due to low accrual.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.